香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 根據上市規則第 13.51B(2)條及第 13.51(2)條作出的公告 本公告由石藥集團有限公司（「本公司」，連同其附屬公司，統稱「本集團」）根據香港聯合交易所有限 公司證券上市規則（「上市規則」）第13.51B(2)條及第13.51(2)條作出。 本公司獲本公司執行董事潘衛東先生（「潘先生」）告知，其近日收到中華人民共和國證券監督管理委 員會（「中證監」）有關以下事情向其出具《行政處罰決定書》（「決定書」）： -1- 1. 根據本公司間接非全資附屬公司石藥創新製藥股份有限公司（「石藥創新」，其股份於深圳證券 交易所創業板上市，股份代碼：300765）於2023年12月8日發佈的公告，本公司全資附屬公司石 藥集團恩必普藥業有限公司（「恩必普」，為石藥創新的最大股東)擬自2023年12月8日起六個月 內，擇機增持石藥創新的股份上限不超過人民幣一億元。 2. 於2024年1月10日，石藥創新發佈了擬收購本公 ...

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest and market performance [1][2]. Group 1: Fund Performance - As of October 31, 2024, the Hong Kong Innovative Drug ETF (159567) closed with a gain of 5.46% and a trading volume of 3.327 billion yuan [1]. - The fund's share volume increased by 1968.65% from 3.95 million shares at the end of 2023 to 81.79 million shares by October 30, 2024 [1]. - The fund's size grew by 1650.00%, from 378 million yuan to 6.612 billion yuan during the same period [1]. Group 2: Liquidity - Over the last 20 trading days, the cumulative trading amount for the fund reached 23.202 billion yuan, with an average daily trading amount of 1.16 billion yuan [1]. - Year-to-date, the cumulative trading amount for the fund is 234.346 billion yuan, averaging 1.172 billion yuan per day over 200 trading days [1]. Group 3: Fund Management - The current fund manager, Ma Jun, has managed the Hong Kong Innovative Drug ETF (159567) since its inception, achieving a return of 64.72% during the management period [2]. - The fund's top holdings include companies such as BeiGene, CanSino Biologics, Innovent Biologics, and others, with significant percentages of the portfolio allocated to these stocks [2].

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (71.15%), COSCO Shipping Energy (70.14%), and GCL-Poly Energy (70.09%) [1][2] - The companies with the largest increase in holding amounts over the last five trading days are CNOOC (+2.183 billion), SMIC (+2.136 billion), and Tencent (+1.679 billion) [1][2] - The companies with the largest decrease in holding amounts over the last five trading days are Alibaba (-1.659 billion), Tracker Fund (-1.405 billion), and CSPC Pharmaceutical (-1.324 billion) [1][3] Hong Kong Stock Connect Holding Ratios - China Telecom (00728): 9.876 billion shares, 71.15% [2] - COSCO Shipping Energy (01138): 909 million shares, 70.14% [2] - GCL-Poly Energy (01330): 283 million shares, 70.09% [2] - Other notable companies include China Shenhua (67.76%) and Tianjin Capital Environmental Protection (66.42%) [2] Recent Increases in Holdings - CNOOC (00883): +2.183 billion, +10.9063 million shares [2] - SMIC (00981): +2.136 billion, +2.6983 million shares [2] - Tencent (00700): +1.679 billion, +257.85 thousand shares [2] - Other companies with significant increases include China Mobile (+1.498 billion) and Meituan (+1.186 billion) [2] Recent Decreases in Holdings - Alibaba (09988): -1.659 billion, -964.24 thousand shares [3] - Tracker Fund (02800): -1.405 billion, -5.3224 million shares [3] - CSPC Pharmaceutical (01093): -1.324 billion, -17.72074 million shares [3] - Other companies with notable decreases include Li Auto (-894 million) and BYD Company (-370 million) [3]

Core Points - The 2025 National Medical Insurance Directory negotiations have officially commenced, highlighting the importance of pharmaceutical innovation and patient access to medications [1] - The atmosphere at the negotiations is characterized by a cautious and low-key approach from pharmaceutical representatives, with an increased emphasis on confidentiality [3][4] - A total of 535 drugs are under review, with 311 outside the directory and 224 within it, alongside 121 high-value drugs reviewed under the commercial insurance innovation drug directory [9][10] Group 1: Negotiation Atmosphere - The entry process for pharmaceutical representatives was notably quieter and more orderly compared to previous years, reflecting a more subdued approach [3][4] - Representatives from both domestic and multinational pharmaceutical companies, including notable names like 恒瑞医药 and 阿斯利康, participated in the negotiations [4][9] Group 2: Key Drug Categories - Antibacterial drugs are expected to be a significant focus in the afternoon session of the negotiations, with specific products like 万古霉素 being highlighted [9][10] - Innovative drugs, including CAR-T products and new lipid-lowering medications, are also under consideration, with 恒瑞医药 presenting multiple products for initial review [10][12] Group 3: Market Insights - The PCSK9 inhibitor 瑞卡西单抗 has gained attention for its long-acting properties, with a market size of 1.32 billion yuan in 2023, representing 7.8% of the national lipid-lowering drug market [10][11] - The long-acting 阿立哌唑微球 from 丽珠集团 is another product of interest, potentially replacing oral formulations and capturing market share if included in the insurance directory [12]

Group 1: Market Performance - The Hong Kong Innovative Drug Selected ETF (520690) increased by 0.22%, with the latest price at 0.89 yuan as of October 29, 2025 [3] - The ETF recorded a turnover of 4.25% during the trading session, with a total transaction value of 21.78 million yuan [3] - Over the past year, the average daily transaction volume of the ETF was 120 million yuan [3] Group 2: Clinical Data and Industry Insights - Grail presented initial data from its multi-cancer early detection product Galleri at the 2025 ESMO annual meeting, showing a positive predictive value of 61.6% and a specificity of 99.6% [3] - Among the detected new cancers, 69.3% were in stages I-III, with a tissue origin accuracy of 91.7% [3] - Guosen Securities views this data as a significant milestone in the multi-cancer early detection field, suggesting Galleri could enhance existing screening systems [3] Group 3: Company Earnings and Trends - Over 280 pharmaceutical and biotech companies, including Heng Rui Pharmaceutical and WuXi AppTec, reported strong Q3 results, driven by advancements in R&D pipelines and new drug launches [3] - The overall industry is exhibiting a positive trend characterized by "innovation as a foundation and overseas expansion" [3] Group 4: CDMO Sector Performance - Lonza, a leading overseas CDMO, reported strong Q3 results, maintaining a revenue growth forecast of 20-21% for the year, with core EBITDA margins between 30-31% [4] - Medpace has seen consecutive growth in new orders for two quarters, indicating a recovering financing environment for U.S. small and mid-sized biotech firms [4] - WuXi AppTec exceeded Q3 performance expectations and raised its full-year guidance, further confirming the positive outlook for the CXO industry [4] Group 5: ETF Size and Inflows - The latest size of the Hong Kong Innovative Drug Selected ETF reached 512 million yuan, marking a new high since its inception [4] - The ETF's share count also hit a record high of 574 million shares [4] - In the past five days, the ETF experienced continuous net inflows, with a peak single-day net inflow of 31.48 million yuan, totaling 82.81 million yuan in net inflows [4]

智通财经APP获悉，根据2025年10月28日披露数据，中国电信（00728）、中远海能（01138）、绿色动 力环保（01330）位居港股通持股比例前3位，分别为71.18%、70.26%、70.25%。此外，中国海洋石油 （00883）、中芯国际（00981）、美团-W（03690）在最近有统计数据的5个交易日内，持股额增幅最 大，分别为+30.09亿元、+17.46亿元、+13.64亿元;华虹半导体（01347）、石药集团（01093）、中国生 物製药（01177）在最近有统计数据的5个交易日内，持股额减幅最大，分别为-14.99亿元、-12.09亿 元、-6.06亿元。 备注：以上数据由智通机器人根据港交所数据，经过人工智能运算后自动生成，并不保证数据100%准 确；持股额变动=变动持股数*昨日收盘价。 3、港股通最近5个交易日减持榜（前10名） 公司名称 持股额变动 持股数变动 华虹半导体(01347) -14.99亿元 -1740.38万股 石药集团(01093) -12.09亿元 -15715.80万股 中国生物製药(01177) -6.06亿元 -8613.88万股 招金矿业(01818) - ...

Core Insights - The article highlights the net inflow and outflow of funds for various companies in the Hong Kong stock market, indicating significant movements in investor sentiment and market dynamics [1][2][3] Net Inflow Summary - Meituan-W (03690) leads with a net inflow of 653 million, representing a 12.11% increase in its closing price to 100.600 [2] - Semiconductor Manufacturing International Corporation (00981) follows with a net inflow of 590 million, with an 8.04% increase in its closing price to 80.000 [2] - China National Offshore Oil Corporation (00883) has a net inflow of 570 million, showing a 0.50% increase in its closing price to 20.020 [2] - Other notable inflows include Tencent Holdings (00700) with 374 million and a 0.71% increase, and Horizon Robotics-W (09660) with 349 million and a 6.35% increase [2] Net Outflow Summary - CSPC Pharmaceutical Group (01093) experiences the highest net outflow of 650 million, with a 3.90% decrease in its closing price to 7.890 [2] - Pop Mart International (09992) follows with a net outflow of 642 million, down 0.86% to 230.400 [2] - UBTECH Robotics (09880) sees a net outflow of 295 million, with a 6.81% increase in its closing price to 142.700 [2] - Other significant outflows include BYD Electronic (00285) with 249 million and a 1.97% increase, and Jingtai Holdings (02228) with 184 million and a 2.98% increase [2] Net Inflow Ratio Summary - China Merchants Port (00144) leads with a net inflow ratio of 69.84%, closing at 15.210 with a 0.40% increase [3] - Greentown Service (02869) follows with a 64.68% net inflow ratio, closing at 4.680 with a 1.30% increase [3] - Tong Ren Tang Technologies (03613) has a net inflow ratio of 63.56%, closing at 8.710 with a 0.80% decrease [3] Net Outflow Ratio Summary - E Fund Hang Seng ESG (03039) shows a net outflow ratio of -100.00%, closing at 3.902 with a 0.88% increase [3] - 康诺亚-B (02162) has a net outflow ratio of -58.25%, closing at 59.100 with a 2.80% decrease [3] - SF Express (06936) follows with a -56.29% net outflow ratio, closing at 36.860 with a 0.54% decrease [3]

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 1.32% with a trading volume of 588 million yuan on October 28, 2024 [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of October 27, 2024, the fund's latest share count was 8.177 billion shares, with a total size of 6.823 billion yuan, reflecting a significant increase in both share count and size compared to the previous year [1] Fund Performance - The fund's share count increased by 1968.15% and its size increased by 1706.06% from December 31, 2023, when it had 395 million shares and a size of 378 million yuan [1] - The fund has recorded a total trading amount of 22.001 billion yuan over the last 20 trading days, averaging 1.1 billion yuan per day [1] - Year-to-date, the cumulative trading amount is 229.668 billion yuan, with an average daily trading amount of 1.166 billion yuan [1] Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 66.90% during the management period [2] - The top holdings of the fund include companies such as BeiGene, CanSino Biologics, Innovent Biologics, and others, with significant percentages of the portfolio allocated to these stocks [2] - The largest holding is BeiGene, accounting for 10.62% of the portfolio, followed by CanSino Biologics at 10.55% and Innovent Biologics at 10.21% [2]

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (71.16%), Gree Power Environmental (70.40%), and COSCO Shipping Energy (70.32%) [1] - In the last five trading days, the largest increases in holding amounts were seen in CNOOC (+2.948 billion), Pop Mart (+2.005 billion), and SMIC (+1.319 billion) [1] - The largest decreases in holding amounts were recorded for Hua Hong Semiconductor (-1.093 billion), Hang Seng China Enterprises (-603 million), and CSPC Pharmaceutical (-596 million) [2] Group 1: Hong Kong Stock Connect Holding Ratios - China Telecom (00728) has a holding ratio of 71.16% with 9.876 billion shares [1] - Gree Power Environmental (01330) has a holding ratio of 70.40% with 285 million shares [1] - COSCO Shipping Energy (01138) has a holding ratio of 70.32% with 911 million shares [1] Group 2: Recent Increases in Holdings - CNOOC (00883) saw an increase of 2.948 billion in holding amount, with a change of 14.69495 million shares [1] - Pop Mart (09992) experienced an increase of 2.005 billion in holding amount, with a change of 8.5892 million shares [1] - SMIC (00981) had an increase of 1.319 billion in holding amount, with a change of 1.59294 million shares [1] Group 3: Recent Decreases in Holdings - Hua Hong Semiconductor (01347) had a decrease of 1.093 billion in holding amount, with a change of -12.6364 million shares [2] - Hang Seng China Enterprises (02828) saw a decrease of 603 million in holding amount, with a change of -6.2396 million shares [2] - CSPC Pharmaceutical (01093) experienced a decrease of 596 million in holding amount, with a change of -7.65722 million shares [2]

Core Insights - The article highlights the net inflow and outflow of funds for various companies in the Hong Kong stock market, indicating significant movements in capital investment [1][2]. Net Inflow Summary - China Mobile (00941) leads with a net inflow of 1.131 billion, representing a 42.43% increase in investment [2]. - China National Offshore Oil Corporation (00883) follows with a net inflow of 979 million, showing a 28.62% increase [2]. - Pop Mart (09992) ranks third with a net inflow of 782 million, but its share price decreased by 9.36% [2]. Net Outflow Summary - Hua Hong Semiconductor (01347) experiences the highest net outflow at -1.018 billion, with a decrease of 22.36% [2]. - The iShares Asia 50 ETF (02800) has a net outflow of -795 million, reflecting a 6.53% decrease [2]. - Stone Pharmaceutical Group (01093) sees a net outflow of -488 million, with a 26.11% drop in investment [2]. Net Inflow Ratio Summary - GX Hangseng Technology (02837) has the highest net inflow ratio at 67.25%, with a net inflow of 14.7513 million [3]. - Tong Ren Tang (03613) follows with a net inflow ratio of 65.42%, amounting to 4.8958 million [3]. - Shenwei Pharmaceutical (02877) ranks third with a net inflow ratio of 54.29%, totaling 3.1420 million [3]. Net Outflow Ratio Summary - The Wisdom Hong Kong 100 ETF (02825) shows a net outflow ratio of -100.00%, with a total outflow of -5.972 million [3]. - China International Marine Containers (02039) has a net outflow ratio of -63.47%, amounting to -19.7122 million [3]. - Eagle Holdings (00041) follows with a net outflow ratio of -60.44%, totaling -5.7119 million [3].